Christopher Hanson is a highly qualified, experienced, and widely respected regulator. He is a great choice to lead the NRC at such an important time, as the agency continues to modernize and as a new generation of advanced reactors with inherent safety features move through the licensing process.
“This has been an exciting quarter for the company, with the launch of the Department of Energy’s Advanced Reactor Demonstration Program – which could jump-start commercial demand for HALEU – and our successful capital raise,” said Daniel B. Poneman, Centrus president and chief executive officer. “Construction of our HALEU demonstration plant is on schedule and on budget, and we are poised to be first to market with this promising new fuel when the demonstration is completed in 2022. We are continuing our efforts to improve our capital structure, having raised approximately $25 million and launched our tender offer to retire up to $60 million of the preferred.”
Terrestrial Energy USA and Centrus Energy Corp. have signed a memorandum of understanding to secure fuel supply for a future fleet of Integral Molten Salt Reactor (IMSR) power plants. The two companies will evaluate the logistical, regulatory, and transportation requirements to establish fuel supply for Integral Molten Salt Reactor (IMSR) power plants, which use standard-assay low-enriched uranium (LEU).
TerraPower announced today its plans to team with Centrus Energy Corp. to establish commercial-scale, domestic production capabilities for high-assay, low-enriched uranium (HALEU), which will be needed to fuel many next-generation reactor designs including the recently announced Natrium™ Power Storage System designed by TerraPower and GE Hitachi Nuclear Energy.
The Russian Suspension Agreement is a trade agreement between the United States and Russia that suspends an antidumping duty investigation of Russian uranium and allows for limited imports, subject to an annual quota.
Centrus Energy Corp. today announced the pricing of an underwritten public offering of 2,350,000 shares of its Class A Common Stock, at a public offering price of $10.00 per share of Class A Common Stock. In addition, Centrus has granted the underwriters a 30-day option to purchase up to an additional 352,500 shares of Class A Common Stock at the public offering price, less the underwriting discount.
“Despite the unprecedented health crisis posed by COVID-19, with a large portion of our staffshifting to telework, our dedicated employees have rallied to produce outstanding results,” said Dan Poneman, Centrus president and chief executive officer. “We are continuing to make progress on the High-Assay, Low-Enriched Uranium (HALEU) program, including the NuclearRegulatory Commission’s acceptance of our application to amend our license at Piketon to permit the production of HALEU for review. We will continue our efforts to protect the healthand safety of our employees and their families as our highest priority.”